Recently, in a Chinese MM cohort involving RRMM patients treated with anti-BCMA CAR-T cell therapy, a Cox model based on extramedullary disease, light-chain MM, high-risk cytogenetics, and more than three therapeutic lines allowed the early identification of cases with poor PFS (34). Here, TNFRSF17 is linked to Miyoshi myopathy.